0

524636

OXYGENTAPH

img img img img
No Data Available

OXYGENTA PHARMACEUTICAL LIMITE Share Price Update

As of the latest trading session, OXYGENTA PHARMACEUTICAL LIMITE is trading at ₹55, down by ₹-2.41 or -4.19% from its previous close. The stock has moved between ₹54.06 and ₹59.88 today. Over the past year, the stock has delivered a return of -29.06%. In the last month, it has returned 22.23%.

Investment Returns

Over 1 Month 22.23% Over 3 Months -2.37% Over 6 Months -3.01% Over 1 Year -29.06%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

OXYGENTA PHARMACEUTICAL LIMITE fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 205.20
  • P/E Ratio (TTM) -11.76
  • Beta 1.32
  • Book Value / share -9.91
  • Return on equity 0.00%
  • EPS (TTM) 0.00
  • Dividend yield [-]%
  • Net profit/quarter (Cr) -4.84
info icon alternate text

OXYGENTA PHARMACEUTICAL LIMITE Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 33.93
Operating Expense 40.26
Net Profit -4.84
Net Profit Margin (%) -14.26
Earnings Per Share (EPS) -1.32
EBITDA -4.08
Effective Tax Rate (%) 23.38
Particulars SEP 2025 (Values in Cr)
Revenue 14.30
Operating Expense 20.68
Net Profit -4.93
Net Profit Margin (%) -34.47
Earnings Per Share (EPS) -1.33
EBITDA -4.63
Effective Tax Rate (%) 23.44
Particulars JUN 2025 (Values in Cr)
Revenue 15.13
Operating Expense 23.43
Net Profit -6.11
Net Profit Margin (%) -40.38
Earnings Per Share (EPS) -1.65
EBITDA -6.67
Effective Tax Rate (%) 25.03
Particulars MAR 2025 (Values in Cr)
Revenue 49.47
Operating Expense 53.05
Net Profit -2.15
Net Profit Margin (%) -4.34
Earnings Per Share (EPS) -0.60
EBITDA -1.90
Effective Tax Rate (%) 43.42
Particulars DEC 2024 (Values in Cr)
Revenue 33.21
Operating Expense 38.66
Net Profit -3.93
Net Profit Margin (%) -11.83
Earnings Per Share (EPS) 1.07
EBITDA -3.86
Effective Tax Rate (%) 20.76
Particulars MAR 2025 (Values in Cr)
Revenue 109.30
Operating Expense 124.69
Net Profit -10.30
Net Profit Margin (%) -9.42
Earnings Per Share (EPS) -2.86
EBITDA -8.96
Effective Tax Rate (%) 28.22
Particulars MAR 2024 (Values in Cr)
Revenue 39.64
Operating Expense 53.59
Net Profit -3.48
Net Profit Margin (%) -8.77
Earnings Per Share (EPS) -1.09
EBITDA -9.62
Effective Tax Rate (%) 74.90
Particulars MAR 2023 (Values in Cr)
Revenue 30.99
Operating Expense 41.65
Net Profit -11.57
Net Profit Margin (%) -37.33
Earnings Per Share (EPS) -6.36
EBITDA -7.82
Effective Tax Rate (%) -1.75
Particulars MAR 2022 (Values in Cr)
Revenue 60.52
Operating Expense 61.56
Net Profit -0.61
Net Profit Margin (%) -1.00
Earnings Per Share (EPS) -0.48
EBITDA 2.02
Effective Tax Rate (%) -24.48
Particulars MAR 2021 (Values in Cr)
Revenue 52.03
Operating Expense 51.18
Net Profit 2.93
Net Profit Margin (%) 5.63
Earnings Per Share (EPS) 2.87
EBITDA 6.11
Effective Tax Rate (%) 6.38
Particulars MAR 2025 (Values in Cr)
Book Value / Share -6.77
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -7.97
Particulars MAR 2024 (Values in Cr)
Book Value / Share -6.18
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -24.27
Particulars MAR 2023 (Values in Cr)
Book Value / Share -32.53
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -25.27
Particulars MAR 2022 (Values in Cr)
Book Value / Share -24.38
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 2.43
Particulars MAR 2021 (Values in Cr)
Book Value / Share -37.27
ROE % -5.79
ROCE % 7.89
Total Debt to Total Equity 0.00
EBITDA Margin 7.55
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.12
Total Assets 83.42
Total Liabilities 83.42
Total Equity -25.02
Share Outstanding 3
Price to Book Ratio -11.75
Return on Assets (%) -11.60
Return on Capital (%) -26.02
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.10
Total Assets 63.19
Total Liabilities 63.19
Total Equity -20.12
Share Outstanding 3
Price to Book Ratio -4.69
Return on Assets (%) -5.50
Return on Capital (%) -9.38
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.10
Total Assets 54.26
Total Liabilities 54.26
Total Equity -46.20
Share Outstanding 1
Price to Book Ratio -1.13
Return on Assets (%) -21.32
Return on Capital (%) -53.09
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.15
Total Assets 31.17
Total Liabilities 31.17
Total Equity -34.62
Share Outstanding 1
Price to Book Ratio -0.99
Return on Assets (%) -1.95
Return on Capital (%) -3.49
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.44
Total Assets 33.86
Total Liabilities 33.86
Total Equity -38.01
Share Outstanding 1
Price to Book Ratio 0.00
Return on Assets (%) 8.65
Return on Capital (%) 29.69
Particulars MAR 2025 (Values in Cr)
Net Income -11.55
Cash from Operations 2.76
Cash from Investing -11.24
Cash from Financing 8.66
Net change in Cash 0.02
Free Cash Flow 14.15
Particulars MAR 2024 (Values in Cr)
Net Income -13.87
Cash from Operations -13.04
Cash from Investing -4.08
Cash from Financing 17.13
Net change in Cash 0.00
Free Cash Flow -8.94
Particulars MAR 2023 (Values in Cr)
Net Income -11.37
Cash from Operations -1.63
Cash from Investing -9.63
Cash from Financing 11.22
Net change in Cash -0.04
Free Cash Flow 8.01
Particulars MAR 2022 (Values in Cr)
Net Income -0.48
Cash from Operations -1.55
Cash from Investing -4.94
Cash from Financing 6.33
Net change in Cash -0.28
Free Cash Flow 3.38
Particulars MAR 2021 (Values in Cr)
Net Income 3.14
Cash from Operations -1.40
Cash from Investing -6.71
Cash from Financing 8.66
Net change in Cash 0.32
Free Cash Flow 5.33
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 35.19 15.23 1.82 269.67 23.12 41.00
BLISS GVS PHARMA LTD 262.60 25.11 2.45 2778.02 105.05 277.80
CIPLA LTD 1294.75 22.00 3.17 104587.66 1165.55 1672.20
FERMENTA BIOTECH LIMITED 319.05 10.61 2.40 939.00 252.15 399.00
GLAXOSMITHKLINE PHARMA LT 2473.05 41.65 24.53 41894.96 2218.00 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 35.19 33.84 4.90 269.67 23.12 41.00
AMRUTANJAN HEALTH CARE LTD. 575.55 28.78 4.86 1663.95 490.00 789.95
ASTRAZENECA PHARMA IND LT 8501.75 102.17 26.60 21254.38 7630.00 10653.05
BLISS GVS PHARMA LTD 262.60 35.78 2.51 2778.02 105.05 277.80

OXYGENTA PHARMACEUTICAL LIMITE shareholding pattern

Holding
43.43%
56.53%
0.02%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

OXYGENTA PHARMACEUTICAL LIMITE Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
55.49 -3.34 redarrow
red-green-graph indicator
8 Bearish
8 Bullish
  • 5 Days 56.70
  • 26 Days 53.80
  • 10 Days 55.90
  • 50 Days 53.60
  • 12 Days 55.50
  • 100 Days 56.30
  • 20 Days 54.30
  • 200 Days 62.50
56.36 PIVOT
First Support 55.09 First Resistance 58.88 Second Support 52.57 Second Resistance 60.15 Third Support 51.30 Third Resistance 62.67
RSI 60.29 ADX 57.74 MACD 1.61 Williams % R -44.32 Commodity Channel Index (CCI) 64.17
Date 2026-04-24 Week 3464.00 Same Day 2940.00 Month 3986.00
1 Year 1.34 3 Year 0.73
Over 1 Month
22.23% down
Over 1 Year
-29.06% down
Over 3 Months
-2.37% down
Over 3 Years
22.46% down
Over 6 Months
-3.01% down
Over 5 Years
43.19% down

OXYGENTA PHARMACEUTICAL LIMITE Corporate Actions

Top Gainers

Top Losers

OXYGENTA PHARMACEUTICAL LIMITE Share Price

Oxygenta Pharmaceutical Limited was initially incorporated as S S Organics Private Limited as a private limited Company in 1990. The Company converted its status to a Public Limited Company in 1993 changing the name to S S Organics Limited. Further, it was changed to Oxygenta Pharmaceutical Limited in FY 2021-22.

The Company was incorporated with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals. It manufactures a wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs. The Company has plant located at Medak in Andhra Pradesh.

The Company is strong in manufacturing of anti ulcerative and anti bacterial drugs. The Company is doing contract manufacturing work for APL and also having its own production. Apart from these, it is doing contract manufacturing work with APL for manufacturing of Cirprofloxacin HCL from Q-Acid and has been manufacturing Pantaprozole Sodium and Gabapentine for own production. This contract manufacturing helped the Company to meet major operational expenses. Since the Company started commercial production in July, 2015 after fire accident tragedy, it is in process of stabilizing the manufacturing and marketing.

Parent organization Indian Private
NSE symbol [-]
Founded 1990
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Oxygenta Pharmaceutical Ltd?

Answer Field

Oxygenta Pharmaceutical Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 55.49 as on Apr 28 2026 03:26 PM.

What is the Market Cap of Oxygenta Pharmaceutical Ltd Share?

Answer Field

The market cap of Oxygenta Pharmaceutical Ltd for NSE ₹ 0.00 & for BSE ₹ 205.20 as on Apr 28 2026 03:26 PM.

What is the 52 Week High and Low of Oxygenta Pharmaceutical Ltd?

Answer Field

The 52 Week High and Low of Oxygenta Pharmaceutical Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 133.50 and ₹ 45.30.

What is 1 year return for Oxygenta Pharmaceutical Ltd?

Answer Field

The 1 year returns on the stock has been -36.98%.

What is the P/E Ratio of Oxygenta Pharmaceutical Ltd Share?

Answer Field

As on Apr 28 2026 03:26 PM the price-to-earnings (PE) ratio for Oxygenta Pharmaceutical Ltd share is -11.76.

What is the PB ratio of Oxygenta Pharmaceutical Ltd Share?

Answer Field

As on Apr 28 2026 03:26 PM, the price-to-book (PB) ratio for Oxygenta Pharmaceutical Ltd share is -9.91.

How to Buy Oxygenta Pharmaceutical Ltd Share?

Answer Field

You can trade in Oxygenta Pharmaceutical Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Oxygenta Pharmaceutical Ltd Share on Bajaj Broking App?

Answer Field

To buy Oxygenta Pharmaceutical Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Oxygenta Pharmaceutical Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|